Health
8TV "JASMINE PROJECT LOVE" PROVIDES HELPING HAND TO THOSE IN NEED
Season 2 Expected to Begin Filming by Year-End PETALING JAYA, Malaysia, July 10, 2024 /PRNewswire/ -- Since its premiere, 8TV's 20th-anniversary special programme, "Jasmine Project Love", has received overwhelming support from various sectors and touched the lives of many in Malaysia. "Jasmine Pr...
2024-07-10 14:18
1775
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year t...
2024-07-10 13:30
3386
3D Artificial Cornea from Stem Cells: Chula Researchers Advance Canine Corneal Wound Treatment
BANGKOK, July 10, 2024 /PRNewswire/ -- Chulalongkorn University's Faculty of Veterinary Science and the Faculty of Engineering have worked together to research and develop a three-dimensional artificial cornea from stem cells that offers a way to treat deep corneal wounds in dogs. The innovation ...
2024-07-10 09:00
2509
USANA Ranked #1 Direct Selling Brand for Calcium Supplements in Hong Kong
Euromonitor International honors USANA Hong Kong for second consecutive year HONG KONG, July 10, 2024 /PRNewswire/ -- USANA Hong Kong was recently recognized as a top brand for calcium supplements by market research giant Euromonitor International. This distinction is based on market research of ...
2024-07-10 07:49
1820
KOSÉ, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells
Demonstration testing of "my own" beauty products PALO ALTO, Calif., July 9, 2024 /PRNewswire/ -- KOSÉ Corporation (Headquarters: Chuo-ku,Tokyo; President: Kazutoshi Kobayashi), I Peace, Inc. (Headquarters:Palo Alto, California, USA; Founder & CEO: Koji Tanabe), and Reju, Inc. (Headquarters: Min...
2024-07-09 23:00
2026
Bestqool Pro Series Redefines the Standard of Red Light Therapy Devices: Cutting-Edge Technology Undergone the Third-party Laboratory Diagnostic Testing
NEW YORK, July 9, 2024 /PRNewswire/ -- Bestqool, as one of the industry's top makers of innovative red light therapy devices for over six years, in recent months proactively sent their Pro Series devices to LightLab International Allentown LLC, a reputable third-party laboratory in the US. Bestqo...
2024-07-09 21:00
2188
Clinion Applauded by Frost & Sullivan for Enabling Interoperability and Continuity in Clinical Trials Management with its eClinical Solutions
Clinion's decentralized clinical trials and innovative eClinical platform enhance accessibility, cost efficiency, ease of use, regulatory compliance, and sustainability in clinical development. SAN ANTONIO, July 9, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the integrated clinical t...
2024-07-09 21:00
1924
Pulnovo Medical Announces Joining PHA's (Pulmonary Hypertension Association) Corporate Committee
SHANGHAI, July 9, 2024 /PRNewswire/ -- Pulnovo Medical, a globally recognized device pioneer in the treatment for pulmonary hypertension and heart failure, has recently announced its partnership with the Pulmonary Hypertension Association (PHA). This partnership not only underscores Pulnovo Medic...
2024-07-09 20:00
1942
Porton J-STAR and Enabling Technologies Consortium Collaboration on Co-processing Platform Technology Development
CHONGQING, China, July 8, 2024 /PRNewswire/ -- Porton J-STAR today announced
that Enabling Technologies Consortium (ETC) has awarded a two-year contract to
J-STAR to collaborate on "Co-processing Platform Technology."
2024-07-08 22:00
1485
Goodix Launches Its Latest Automotive-Grade Bluetooth LE SoC and CGM Solutions at electronica China 2024
SHENZHEN, China, July 8, 2024 /PRNewswire/ -- Goodix Technology today unveiled its Continuous Glucose Monitoring (CGM) solutions and automotive-grade Bluetooth LE SoC at the electronicaChina 2024. Demonstrating a dedication to innovation in sensing and wireless technology, Goodix showcased its la...
2024-07-08 22:00
2187
Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®
* Tergase® poised to capture a fair share of the global hyaluronidase market.
DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc.
2024-07-08 21:00
2008
GEN Z TAKING PROACTIVE STEPS TO ADDRESS MENTAL HEALTH ISSUES
Yet youth body confidence, ADHD and general lack of purpose abound according to new research SYDNEY, July 8, 2024 /PRNewswire/ -- More than half of Gen Zs are increasingly seeking out mental health therapy indicating support is needed for an entire generation of Australians plagued by anxiety an...
2024-07-08 19:41
11096
Cambrex to Expand Stability Storage Business with New Facility in Durham, North Carolina
EAST RUTHERFORD, N.J., July 8, 2024 /PRNewswire/ -- Cambrex today announced the expansion of its stability storage business, Q1 Scientific, which offers environmentally-controlled stability storage services to the pharmaceutical, medical device, and life sciences industries. Q1 Scientific will op...
2024-07-08 18:00
1780
DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer's Disease
BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer's disease (AD). AD is the most frequent ...
2024-07-08 17:23
1414
MGI Tech Partners with Australian Research Council Training Centre CEAStAR to Lead Innovation in Antimicrobial Resistance Solutions
BRISBANE, Australia, July 8, 2024 /PRNewswire/ -- MGI Australia Pty Ltd, subsidiary of MGI Tech Co., Ltd., a company committed to building core tools and technologies that drive innovation in life science, proudly announces its strategic partnership with TheUniversity of Queensland(UQ) led Centre...
2024-07-08 17:14
2364
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME
* The nomination of novel Lp-PLA2 inhibitor DPT0415 for the treatment of DR & DME. * DPT0415 is a highly potent, selective and safe Lp-PLA2 inhibitor with sufficient target engagement at a dose of 0.3 mpk and robust efficacy in the STZ-induced rat DR model. * This project further validates ...
2024-07-08 17:00
1437
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its ...
2024-07-08 16:28
1467
Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics
HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, to...
2024-07-08 14:30
2131
Parents: Discover the Three Essential Pillars of Childcare for Your Child's Optimal Development
JAKARTA, Indonesia, July 2, 2024 /PRNewswire/ -- Morinaga Milk is unveiling the three key pillars of childcare under its latest campaign: Potential-Attention-Nutrition. As a leading brand under Kalbe Nutritionals, Morinaga is launching this campaign to help 21st century parents meet the challeng...
2024-07-08 14:13
1737
BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial
SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-blind, placebo-controlled, dose-ranging phase 2 clinical tri...
2024-07-08 13:41
1580
Week's Top Stories
Most Reposted
Mastercard goes OTP-free in APAC for faster, safer online transactions
[Picked up by 326 media titles]
2024-11-06 09:00Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
[Picked up by 319 media titles]
2024-11-07 09:00
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 309 media titles]
2024-11-12 09:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 284 media titles]
2024-11-12 11:00
Most Read
Mastercard goes OTP-free in APAC for faster, safer online transactions
2024-11-06 09:00
13117
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10117
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7458
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6173
